ATXA secures €2.5m in funding to research new cardiovascular drugs

The company is one of just three Irish companies to secure funding in this latest round

3rd June, 2018
Professor Therese Kinsella of Ataxa Pharmaceuticals

ATXA Therapeutics, a University College Dublin (UCD) life sciences spin-out, which is developing novel therapeutic drugs to treat pulmonary arterial hypertension (PAH), and other related cardiovascular conditions, has secured €2.5 million in funding under the European Union’s Horizon 2020 SME Instrument Programme Phase 2.

The company is one of just three Irish companies to secure funding in this latest round. Only 64 companies from across Europe, out of 1,280 applications, were successful in securing funding...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

Hard Station: the strange world of tech embargoes

More Tech Brian Lloyd 2 months ago

Podcast: CWSI on securing remote workers during lockdown working

Podcast: Avaya on improving connectivity through the crisis

Tinkerer tailors a solution for property owners to save on water bills

More Tech Emmet Ryan 4 months ago